Cutaneous manifestations of COVID-19 in Mexican patients: A case series and review of literature

Juan Carlos Palomo-Pérez1,2, María Elisa Vega-Memije3, David Aguilar-Blancas4, Erik González-Martínez5 and Lucia Rangel-Gamboa5,6

Abstract
China officially recognized atypical pneumonia outbreak in December 2019; on 11 March 2020, the World Health Organization declared COVID-19 as a pandemic that is produced by a new coronavirus, named SARS-CoV-2, of rapid transmissibility, which can be asymptomatic, with mild to severe respiratory symptoms, and with cardiovascular, neurological, gastrointestinal, and cutaneous complications. Considering that the pandemic prolonged more than initially expected was prognostic, it is essential for the medical community to identify the signs and symptoms of COVID-19. Thus, this work’s objectives were to present cases of cutaneous lesions observed in COVID-19 Mexican patients. We register cutaneous lesions in COVID-19 patients referred from internal medicine and otorhinolaryngology services to dermatology. We presented four interesting cases with cutaneous lesions, including exanthema morbilliform, urticaria, chilblains, ecchymosis, and facial edema, and review the available literature. The most frequent cutaneous markers are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes (livedo reticularis and vasculitis) are considered of poor prognosis.

Keywords
COVID-19, SARS-CoV-2, rash, chilblain, urticaria, livedo reticularis, vasculitis

Date received: 28 January 2021; accepted: 1 February 2021

Introduction
The disease called “acute cor pulmonale caused by coronavirus-2” (SARS-CoV-2) was initially described as a respiratory infection that produced severe pneumonia and presented a high transmission rate; the clinical condition was denominated COVID-19 (CoronaVirus Disease 2019); clinical manifestations included cardiac, digestive, neurologic, and cutaneous signs, and severe complications included death. Thus, on 11 March 2020, COVID-19 was declared as a pandemic after a global spread.1 The virus is globally expanding, with more than 92.3 million infected and 1.98 million deaths worldwide, and 1,570,000 confirmed cases and 137,000 deaths in Mexico, by 14 January 2021.

Cutaneous symptoms can be the first in appearance, accompany respiratory symptoms, or be subsequent. Given the limited number (in this pandemic) of internal medicine, emergency, and intensive care clinicians, it is critical that all physicians can identify signs and symptoms associated with COVID-19. Considering that Latin America is the current epicenter of the pandemic, and Europe presented the third wave of new cases, this article’s objectives were, first, to present images of cutaneous lesions observed in COVID-19 patients referred from internal medicine and otorhinolaryngology services to dermatology. We presented four interesting cases with cutaneous lesions, including exanthema morbilliform, urticaria, chilblains, ecchymosis, and facial edema, and review the available literature. The most frequent cutaneous markers are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes (livedo reticularis and vasculitis) are considered of poor prognosis.

Corresponding Author:
Lucia Rangel-Gamboa, Researcher Division, General Hospital Dr. Manuel Gea González, 14080 Ciudad de México, Mexico.
Email: draluciarangel@yahoo.com.mx

1 External Consultation Division, General Hospital Dr. Manuel Gea González, Ciudad de México, México
2 Tláhuac General Hospital, Ciudad de México, México
3 Dermatology Department, General Hospital Dr. Manuel Gea González, Ciudad de México, México
4 Health Centre T-II San Salvador Cuauchitenco, Milpa Alta, México
5 Ecology of Pathogenic Agents Department, Researcher Division, General Hospital Dr. Manuel Gea González, Ciudad de México, México
6 Private Practice, Luminox Skin Centre, Ciudad de México, México

1177/2020313X21997194 journals.sagepub.com/home/sco
patients and, second, to perform a review of the available literature on COVID-19 and skin manifestations.

We register cutaneous lesions in COVID-19-diagnosed patients referred by internal medicine and otorhinolaryngology (ORL) services. We review eight patients who presented cutaneous manifestations associated with COVID-19. According to the Helsinki Declaration of Human Rights, only four authorized the presentation of their pictures and details of their cases, given their written consent.

Case reports

Case 1
A female patient, 43-year-old nurse working in COVID area of the tertiary General Hospital, presented with facial edema and facial erythema (Figure 1(a)); after 48 h of evolution, she also presented odynophagia and general malaise; the COVID-19 test reported positive 2 days later. She was managed with rest at home and general measures, and no other complications were reported. After 15 days, decreased edema resulted in facial flaccidity and an aged appearance without other sequelae.

Case 2
In June 2020, a 45-year-old female lawyer presented to an ORL physician with general malaise, odynophagia, ageusia, and fever. COVID-19 was confirmed by polymerase chain reaction test (PCR) test. She was managed with rest at home and with antipyretic and analgesic medications. One week after diagnosis and an initial improvement in odynophagia, she developed cutaneous lesions characterized by morbilliform rash, edema, and erythema in hands and feet, and few ecchymoses in the abdomen, legs, and arms (Figure 1(b)–(d)); she also reported hemicrania headache, and distal pain. Initial laboratories only reported low levels of ketones and proteins in urine; hematic biometrics, clotting times, D-dimer, and C-reactive protein were in normal values. She received loratadine/betamethasone 5/0.25 mg VO twice a day with partial improvement, but 10 days later, the distal edema intensified and more ecchymosis was present. At this moment, laboratories reported blood in urine sample, with increased D-dimer and C-reactive protein; thus, prednisone 50 mg/day was started. She showed clinical improvement, and 4 weeks later, laboratory values returned to normal, but still intermittent hand erythema was present and she was continued in clinical observation by telemedicine consultation weekly until complete recovery 8 weeks later.

Case 3
Beginning March 2020, a 37-year-old female patient who had a recent voyage outside Mexico presented with fever, diarrhea, general malaise, and cutaneous distal erythema in toes (Figure 2(a)). Laboratory studies reported leukocytosis and denied bacterial or parasitic gastrointestinal infection. Thus, COVID-19 test was demanded and COVID-19 infection was confirmed. The patient was treated with hydric support, antipyretics, vitamin complex, and loratadine/betamethasone 5/0.25 mg. After 2 weeks, she was asymptomatic.

Case 4
In July 2020, a 39-year-old female consulted a general physician with odynophagia, pharyngeal erythema, geographic tongue, and general malaise. The PCR COVID-19 test confirmed COVID-19 suspicion. Also, her husband presented respiratory signs of COVID-19 and laboratory confirmation but without other signs. A few days later, she presented morbilliform erythema, finger paleness, and distal paresthesia and still had pharyngeal symptoms present (Figure 2(b) and...
Thus, she was evaluated by a dermatologist, who after clinical and laboratory evaluation found no other causes of cutaneous symptoms more than COVID-19 infection. Rest at home, isolation, painkillers, and subsequent follow-up were indicated. In addition, blood count and D-dimer were demanded to complete the evaluation, but the patient did not return for the next appointment. Three weeks later, she was contacted by telephone and reported no cutaneous symptoms, but persistent odynophagia and pharyngeal pain.

**Discussion**

**COVID-19 general aspects**

COVID-19 is produced by SARS-CoV-2, a spherical virus which is single-stranded and has a positive-sense RNA of 30,000 bp; it belongs to the family Coronaviridae and is related to SARS-CoV and coronavirus isolated from bats.\(^2,3\) It has structural proteins named spike (S), nucleocapsid (N), membrane (M), and envelope (E) and 16 nonstructural proteins.\(^4\) SARS-CoV-2 compared with SARS-CoV and MERS-CoV has faster transmissibility, which is transferred from person to person, like influenza. The rapid spread is a well-proven fact, as well transmission by asymptomatic carriers. SARS-CoV-2 was identified in feces and is thought to be a fecal–oral transmission. Symptoms appear 2–14 days after exposure. The infection may be asymptomatic or have symptoms that vary from moderate to severe, even causing death.\(^5,6\) It affects people of any age, showing a more benign course in children and young people;\(^7\) the highest mortality rate was observed in older men, especially those with comorbidities such as diabetes, cardiovascular or pulmonary diseases, obesity, and smoking.\(^8,9\) Poor prognosis has been associated with organ damage produced by hyperinflammatory response.\(^10\)

Coronavirus-2 uses the angiotensin-converting enzyme (ACE) type-2 (ECA2) to enter the tissues. ECA2 is overexpressed in patients with high blood pressure and diabetes mellitus, which could be associated with a worse prognosis.\(^11,12\) ECA2 is found in many tissues, including the lungs, gastrointestinal system, and skin.\(^13\)

The most common symptoms include fever, dry cough, general discomfort, anorexia, shortness of breath, rhinorhea, ageusia, anosmia, chills, myalgia, and chest pain. Moreover, there may be gastrointestinal, cardiac,\(^14\) neurological,\(^15\) hematological, and cutaneous symptoms. Laboratory studies may find lymphocytopenia and thrombocytopenia, elevated liver function marker, and inflammation values.\(^16\) Increases in the white count with lymphocytopenia, elevated prothrombin times, and elevated D-dimer, interleukin-6, C-reactive protein, and procalcitonin are considered poor prognosis.\(^17\)

Dermatosis can occur in 20% of COVID-19 cases, precede the general or respiratory symptoms, and present together with these or during the disease course.\(^18,19\) There are dermatoses directly associated with the infectious process by COVID-19, such as rash and urticaria.\(^20\) The present case series only showed skin manifestations associated with COVID-19 in patients that they general condition not demanded hospital management and were evaluated by the dermatologist in external consultation; it is interesting that all patients are middle-aged women, with an average of 41 years. Two of them had other family members positive for COVID-19 but without skin symptoms. Nevertheless, it is important to remember that some skin manifestations have been reported in complicated patients and are associated with poor prognosis.

**Cutaneous manifestation associated with COVID-19 (literature review)**

**Erythema multiforme**. Lesions like erythema multiforme were reported more frequently in patients in the age range of 58–77 years. It first affects the trunk and later spreads to face and arms. Lesions may be erythematous papules or dark center erythematous violaceous plaques, or target lesions

![Figure 2. Case 3: (a) chilblains. Case 4: (b) pharyngeal hyperemia and (c) morbilliform erythema.](image-url)
characteristic of erythema multiforme.9

**Exanthema maculopapular.** This is the most frequent dermatosis in COVID-19, in patients of any age, presenting jointly or a few days after general symptoms.21,22 In infants, it can start on the face and extend to the trunk and limbs, similar to that of roseola from which it differentiates.23 Among the differential diagnoses, in adults, are dengue, Zika, scarlet fever, cytomegalovirus, and so on.24,25

**Vascular Lesions.** Admission of SARS-CoV-2 to cells using ACE leads to the accumulation of angiotensin II, which may contribute to lung damage and vascular dysfunction. Vascular lesions include violaceous maculae, livedo reticularis, nonnecrotic purple, necrotic purple lesions, chilblain, and so on. Livedo reticularis occurs in 6% of patients; it has been associated with poor prognosis and progression to progressive ischemia. Chilblain affects 19% and frequently appears after general and respiratory symptoms. Chilblain as data of SARS-CoV-2 is more frequent in children and young adults and is associated with mild disease and good prognosis but may be accompanied by itching and mild local pain, respiratory and gastrointestinal symptoms, and increased D-dimer, as described in case 3.26,27

**Urticaria.** Erythematous plaques were reported in 19% of patients with COVID-19. They may or may not be accompanied by pyrexia, and it could be the first manifestation of COVID-19, even without other symptoms. These patients can infect others and must remain isolated. Most COVID-19 patients with hives evolved favorably with antihistamines, antipyretics, and general measures. We agree with Abuelgasin et al. in relation to treatment; thus low-dose prednisolone should be considered on an individualized case.28 Urticaria was associated with high mortality, up to 2%.29,30

**Eruption vesicular.** It is described among the five most frequent skin lesions associated with COVID-19, occurs in middle-aged patients, appears before other symptoms, and is associated with intermediate severity of the disease.18,31 It is found in eruptions formed by vesicles, papules, and pustules; grouped in plates; and frequently located in the trunk, plants, and palms. Differential diagnoses include herpes simplex, herpes zoster, varicella zoster, HIV, and parvovirus B19, among others.22

**Conclusion**

The most frequent cutaneous markers in COVID-19 patients are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes such as livedo reticularis, purpura, and vasculitis are considered of poor prognosis.

**Acknowledgements**

Thanks to the patient’s quo who authorized the clinical image publication.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Ethics declaration**

Clinical images included in this article were authorized by the patient’s written consent, according to the Helsinki Declaration, 1975.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article

**ORCID iD**

Lucia Rangel-Gamboa [https://orcid.org/0000-0002-6934-5950](https://orcid.org/0000-0002-6934-5950)

**References**

1. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically III patients with Covid-19. *New Engl J Med* 2020; 382: e70.
2. Kumar S, Stecher G, Li M, et al. MEGA X: molecular evolutionary genetics analysis across computing platforms. *Mol Biol Evolut* 2018; 35: 1547–1549.
3. Mousavizadeh L and Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. *J Microbiol Immunol Infect*. Epub ahead of print 31 March 2020. DOI: 10.1016/j.jmii.2020.03.022.
4. Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* 2020; 368: 779–782.
5. Song JY, Yun JG, Noh JY, et al. Covid-19 in South Korea—challenges of subclinical manifestations. *N Engl J Med* 2020; 382: 1858–1859.
6. Zavascki AP and Falci DR. Clinical characteristics of Covid-19 in China. *N Engl J Med* 2020; 382: 1859.
7. Parri N, Lenge M, Buonsenso D, et al. Children with Covid-19 in pediatric emergency departments in Italy. *N Engl J Med* 2020; 383: 187–190.
8. Aronson L. Age, complexity, and crisis—a prescription for progress in pandemic. *N Engl J Med* 2020; 383: 4–6.
9. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. *N Engl J Med* 2020; 382: 2012–2022.
10. Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. *Curr Probl Cardiol* 2020; 45(8): 100618.
11. Cheng H, Wang Y and Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. *J Med Virol* 2020; 92: 726–730.
12. Mourad JJ and Bernard IL. Interaction between RASS inhibitors and ACE2 in the context of COVID-19. *Nat Rev Cardiol* 2020; 17: 313.
13. Gu J, Han B and Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. *Gastroenterology* 2020; 158(6): 1518–1519.
14. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. *J Am Coll Cardiol* 2020; 75(18): 2352–2371.
15. Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host interaction and proposed neurotropic mechanisms. *ACS Chem Neurosci* 2020; 11: 995–998.
16. Gandhi RT, Lynch JB and del Rion C. Mild or moderate COVID-19. *N Engl J Med* 2020; 383: 1757–1766.
17. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. *N Engl J Med* 2020; 382: 2372–2374.
18. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020; 34: e212–e213.
19. Henry D, Ackerman M, Sancelme E, et al. Urticarial eruption in COVID-19 infection. *J Eur Acad Dermatol Venereol* 2020; 34(6): e244–e245.
20. Duong TA, Velter C, Rybojad M, et al. Did Whatsapp reveal a new cutaneous COVID-19 manifestations? *J Eur Acad Dermatol Venereol* 2020; 34: e348–e350.
21. Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. *Clin Exp Dermatol* 2020; 45(7): 892–895.
22. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestation of COVID-19: report of three cases and a review of literature. *J Dermatol Sci* 2020; 98(2): 75–81.
23. Galvan Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol* 2020; 183: 71–77.
24. Chesser H, Chambliss JM and Zwemer E. Acute hemorrhagic edema of infancy after coronavirus infection with recurrent rash. *Case Rep Pediatr* 2017; 2017: 5637503.
25. Joob B and Wiwanitkit V. COVID-19 can present with a rash be mistaken for dengue. *J Am Acad Dermatol* 2020; 82: e177.
26. Macedo-Perez M, Barragan-Estudillo ZF, Castillo-Montufar E, et al. Dermatological findings in COVID-19 patients: Mexican experience. *Int J Dermatol* 2020; 59(7): 872–873.
27. Andina D, Noguera-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting of COVID-19 pandemic. *Pediatr Dermatol* 2020; 37(3): 406–411.
28. Abuelgasin E, Modaragamage AC, Singh R, et al. Management of urticaria in COVID-19 patients: a systematic review. *Dermatol Ther* 2020; 2020: e14328.
29. Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr* 2020; 2020: e201346.
30. van Damme C, Berlingin E, Saussez S, et al. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. *J Eur Acad Dermatol Venereol* 2020; 34(7): e300–e301.
31. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; 75(7): 1730–1741.
32. Fernandez -Nieto D, Ortega-Quijano J, Jimenez-Cauche J, et al. Clinical and histological characterization of vesicular COVID-19 rashes: A prospective study in a tertiary care hospital. *Clin Exp Dermatol* 2020; 45: 872–875.